| 1 |
Wiström J, Norrby SR, Myhre EB, et al. Frequency of antibiotic-associated diarrhoea in 2462 antibiotic-treated hospitalized patients: a prospective study [J]. J Antimicrob Chemother, 2001, 47(1): 43-50.
|
| 2 |
吴玉姣，朱珊梅，唐风雷. 利福平抗结核致腹泻的临床分析 [J]. 药学与临床研究, 2012, 20(6): 547-548.
|
| 3 |
曹艳菊，张豫生，屈昌民，等. 幽门螺杆菌治疗中抗生素相关性腹泻的预防 [J]. 中华医院感染学杂志, 2006, 16(5): 559-560.
|
| 4 |
张雪梅. 肠道菌群与抗生素相关性腹泻的关系 [J]. 微生物学通报, 2019, 46(9): 2386-2393.
|
| 5 |
周文静. 抗生素相关性腹泻的研究进展 [J]. 实用检验医师杂志, 2011, 3(4): 245-247.
|
| 6 |
Hempel S, Newberry SJ, Maher AR, et al. Probiotics for the prevention and treatment of antibiotic-associated diarrhea: a systematic review and meta-analysis [J]. JAMA, 2012, 307(18): 1959-1969.
|
| 7 |
周慧，李洪福，崔云龙. 酪酸梭菌活菌散与抗菌药间隔序贯应用预防抗生素相关性腹泻疗效观察 [J]. 中国微生态学杂志, 2009, 21(8): 743-744, 746.
|
| 8 |
郑跃杰，黄志华，刘作义，等. 微生态制剂儿科应用专家共识(2010年10月) [J]. 中国实用儿科杂志, 2011, 26(1): 26-29.
|
| 9 |
Guarner F, Khan AG, Garisch J, et al. World Gastroenterology Organisation Global Guidelines: probiotics and prebiotics October 2011 [J]. J Clin Gastroenterol, 2012, 46(6): 468-481.
|
| 10 |
Berry D, Reinisch W. Intestinal microbiota: a source of novel biomarkers in inflammatory bowel diseases? [J]. Best Pract Res Clin Gastroenterol, 2013, 27(1): 47-58.
|
| 11 |
方凯，王艺宙，王慧，等. 益生菌治疗溃疡性结肠炎的研究进展 [J]. 药物生物技术, 2014, 21(3): 270-273.
|
| 12 |
Geier MS, Butler RN, Howarth GS. Inflammatory bowel disease: current insights into pathogenesis and new therapeutic options; probiotics, prebiotics and synbiotics [J]. Int J Food Microbiol, 2007, 115(1): 1-11.
|
| 13 |
王艳，李俊霞，王化虹，等. 溃疡性结肠炎肠道菌群失调与免疫球蛋白水平的相关性 [J]. 实用医学杂志, 2016, 32(10): 1631-1634.
|
| 14 |
雷晓燕，崔梅花. 溃疡性结肠炎的治疗进展 [J]. 山东医药, 2014, 54(6): 99-102.
|
| 15 |
Zocco MA,Verme LZD, Cremonini F, et al. Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis [J]. Aliment Pharmacol Ther, 2006, 23(11): 1567-1574.
|
| 16 |
江学良，张伟，张玉琦，等. 酪酸梭菌活菌胶囊联合美沙拉嗪治疗溃疡性结肠炎的疗效及卫生经济学评价 [J]. 中国微生态学杂志, 2015, 27(11): 57-60, 65.
|
| 17 |
Gionchetti P, Rizzello F, Venturi A, et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial [J]. Gastroenterology, 2000, 119(2): 305-309.
|
| 18 |
Gionchetti P, Rizzello F, Helwig U, et al. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial [J]. Gastroenterology, 2003, 124(5): 1202-1209.
|
| 19 |
Yasueda A, Mizushima T, Nezu R, et al. The effect of Clostridium butyricum MIYAIRI on the prevention of pouchitis and alteration of the microbiota profile in patients with ulcerative colitis [J]. Surg Today, 2016, 46(8): 939-949.
|
| 20 |
沈骏，冉志华，童锦禄，等. 益生菌对炎症性肠病诱导缓解、维持治疗和贮袋炎作用系统评价 [J]. 胃肠病学和肝病学杂志, 2008, 17(2): 36-40.
|
| 21 |
丁姮月，孙宏文. 肠道菌群与腹泻型肠易激综合征相关性的研究进展 [J]. 中国微生态学杂志, 2019, 31(1): 119-124.
|
| 22 |
朱丽明，柯美云，周丽雅，等. 益生菌治疗腹泻型肠易激综合征 [J]. 基础医学与临床, 2008, 28(10): 1070-1074.
|
| 23 |
江学良. 溃疡性结肠炎中西医诊疗手册 [M]. 天津: 天津科学技术出版社, 2020: 1-500.
|
| 24 |
Sikander A, Rana SV, Prasad KK. Role of serotonin in gastrointestinal motility and irritable bowel syndrome [J]. Clin Chim Acta, 2009, 403(1-2): 47-55.
|
| 25 |
中华医学会消化病学分会胃肠动力学组，中华医学会外科学分会结直肠肛门外科学组. 中国慢性便秘诊治指南(2013,武汉) [J]. 中华消化杂志, 2013, 33(5): 291-297.
|
| 26 |
Zoppi G, Cinquetti M, Luciano A, et al. The intestinal ecosystem in chronic functional constipation [J]. Acta Paediatr, 1998, 87(8): 836-841.
|
| 27 |
Agrawal A, Houghton LA, Morris J, et al. Clinical trial: the effects of a fermented milk product containing Bifidobacterium lactis DN-173 010 on abdominal distension and gastrointestinal transit in irritable bowel syndrome with constipation [J]. Aliment Pharmacol Ther, 2009, 29(1): 104-114.
|
| 28 |
Madempudi RS, Neelamraju J, Ahire JJ, et al. Bacillus Coagulans Unique IS2 in Constipation: A Double-Blind, Placebo-Controlled Study [J]. Prob Antimicrob Prot, 2019. [Online ahead of print]
|
| 29 |
Yano JM, Yu K, Donaldson GP, et al. Indigenous bacteria from the gut microbiota regulate host serotonin biosynthesis [J]. Cell, 2015, 161(2): 264-276.
|
| 30 |
邵茗，谭韡，罗和生. 短链脂肪酸参与多种疾病发病机制的研究进展 [J]. 胃肠病学和肝病学杂志, 2019, 28(8): 951-954.
|
| 31 |
Marshall JC. The gut as a potential trigger of exercise-induced inflammatory responses [J]. Can J Physiol Pharmacol, 1998, 76(5): 479-484.
|
| 32 |
Seki E, Schnabl B. Role of innate immunity and the microbiota in liver fibrosis: crosstalk between the liver and gut [J]. J Physiol, 2012, 590(3): 447-458.
|
| 33 |
Aller R, De Luis D, Izaola O, et al. Effect of a probiotic on liver aminotransferases in nonalcoholic fatty liver disease patients: a double blind randomized clinical trial [J]. Eur Rev Med Pharmacol Sci, 2011, 15(9): 1090-1095.
|
| 34 |
李伟娜，袁琳卉，胡豆豆，等. 酪酸梭菌二联活菌胶囊联合多烯磷脂酰胆碱治疗非酒精性脂肪性肝炎患者的疗效观察 [J/CD]. 中国肝脏病杂志(电子版), 2017, 9(3): 80-84.
|
| 35 |
宋献美，吴晓东，石科，等. 地衣芽孢杆菌对非酒精性脂肪肝病的干预作用及对肠黏膜通透性的影响 [J]. 实用医学杂志, 2018, 34(24): 4056-4059.
|
| 36 |
辛晟梁，徐可树. 乳果糖在肝性脑病的应用及其研究进展 [J]. 临床消化病杂志, 2017, 29(3): 184-187.
|
| 37 |
Woodhouse CA, Patel VC, Singanayagam A, et al. Review Article: the Gut Microbiome as a Therapeutic Target in the Pathogenesis and Treatment of Chronic Liver Disease [J]. Aliment Pharmacol Ther, 2018, 47(2): 192-202.
|